SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, are widely approved antihyperglycemic agents that improve insulin resistance (IR) (5), and are used to reduce glycemia and cardiovascular risk in T2DM patients (6).